Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions.
作者： Vanda Markovic-Pekovic , Ranko Škrbić , Brian Godman , Lars L Gustafsson , None
DOI: 10.1586/ERP.12.48
关键词: Drug Utilization 、 Ambulatory care 、 Health insurance 、 Economic growth 、 Observational study 、 Environmental health 、 Medicine
摘要: Background: Multiple reforms have been introduced in the Republic of Srpska to enhance prescribing efficiency. Objectives: First, assess their influence on utilization and expenditure proton-pump inhibitors, statins renin–angiotensin inhibitor drugs. Second, whether can obtain low prices for generics. Third, suggest additional that could be introduced. Methods: Observational study all ambulatory care patients between 2003 2010. Defined daily doses (DDDs) DDDs per 1000 inhabitants day used measuring changes utilization. Reimbursed as health insurance perspective. Results: Increasing three classes. Utilization angiotensin-receptor blockers principally limited by restrictions. expenditure/DDD classes decreased up 82% 2010 versus 2004, appreciably improving efficiency statins. Increased esomeprazole at higher reimbursed expenditure/DDD,...
core.ac.uk
expert-reviews.com参考文章(43)
D. Clark, C. Centeno, J. M. Martin-Moreno, C. Normand, L. Gorgojo, M. Harris, Transforming research into action: A European Parliament report on palliative care Eurohealth. ,vol. 15, pp. 23- 25 ,(2009)
Warren Coats, The Central Bank of Bosnia and Herzegovina Springer, Boston, MA. pp. 367- 399 ,(1999) , 10.1007/978-1-4615-5193-5_14
Catherine Sermet, Veronique Andrieu, Brian Godman, Eric Van Ganse, Alan Haycox, Jean-Pierre Reynier, Ongoing pharmaceutical reforms in France Applied Health Economics and Health Policy. ,vol. 8, pp. 7- 24 ,(2010) , 10.1007/BF03256162
J. Usher-Smith, T. Ramsbottom, H. Pearmain, M. Kirby, Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on International Journal of Clinical Practice. ,vol. 62, pp. 480- 484 ,(2008) , 10.1111/J.1742-1241.2007.01690.X
Enver Zerem, Nedim Hrelja, Proton Pump Inhibitors in the Management of Gastroesophageal Reflux Disease Medicinski arhiv. ,vol. 65, pp. 52- 55 ,(2011)
Brian Godman, Solveig Sakshaug, Christian Berg, Björn Wettermark, Alan Haycox, None, Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Review of Pharmacoeconomics & Outcomes Research. ,vol. 11, pp. 121- 129 ,(2011) , 10.1586/ERP.10.87
Brian Godman, Payers endorse generics to enhance prescribing efficiency : impact and future implications, a case history approach Generics and Biosimilars Initiative journal. ,vol. 1, pp. 69- 83 ,(2012) , 10.5639/GABIJ.2012.0102.017
Silvio Garattini, Vittorio Bertele’, Brian Godman, Alan Haycox, Björn Wettermark, Lars L Gustafsson, Piperska Group, None, Enhancing the rational use of new medicines across European health care systems. European Journal of Clinical Pharmacology. ,vol. 64, pp. 1137- 1138 ,(2008) , 10.1007/S00228-008-0537-Z
Sinem Ezgi Gulmez, Anette Holm, Henrik Frederiksen, Thøger Gorm Jensen, Jesper Hallas, Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. JAMA Internal Medicine. ,vol. 167, pp. 950- 955 ,(2007) , 10.1001/ARCHINTE.167.9.950
Björn Wettermark, Brian Godman, Bengt Jacobsson, Flora M. Haaijer-Ruskamp, Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Applied Health Economics and Health Policy. ,vol. 7, pp. 137- 147 ,(2009) , 10.1007/BF03256147